HCID 16664802, compound → HCID 71253046, compound
Reaction equation
Br[C:2]1[CH:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][N:13]([C:16]3[C:21]([CH:22]4[CH2:24][CH2:23]4)=[CH:20][C:19]([C:25]([F:28])([F:27])[F:26])=[CH:18][N:17]=3)[CH2:12][CH2:11]2)=[O:9])=[C:4]([F:29])[CH:3]=1.[CH3:30][C@@H:31]1[CH2:35][CH2:34][S:33](=[O:37])(=[O:36])[NH:32]1>>[CH:22]1([C:21]2[C:16]([N:13]3[CH2:14][CH2:15][N:10]([C:8]([C:5]4[CH:6]=[CH:7][C:2]([N:32]5[C@H:31]([CH3:30])[CH2:35][CH2:34][S:33]5(=[O:37])=[O:36])=[CH:3][C:4]=4[F:29])=[O:9])[CH2:11][CH2:12]3)=[N:17][CH:18]=[C:19]([C:25]([F:28])([F:27])[F:26])[CH:20]=2)[CH2:24][CH2:23]1Participants
3
Procedure
Using (4-bromo-2-fluorophenyl)[4-(3-cyclopropyl-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]methanone (375 mg) described in Preparation Example 123 and (R)-3-methylisothiazolidine 1,1-dioxide (107 mg) described in Preparation Example 2 and by the reaction and treatment in the same manner as in Example 4, the title compound (122 mg) was obtained.
Workup
- customdescribed in Preparation Example 2 and by the reaction and treatment in the same manner as in Example 4
Sources & evidence
- ORD record
- ord-fda9f0feddfd45ab895c0e9372020412
- Source dataset
- uspto-grants-2014_08
- Patent number
- US08816079B2
Reaction notes
Loading…